Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

High Court Won’t Hear InFuse Off-Label Preemption Case

This article was originally published in The Gray Sheet

Executive Summary

The case would have tested whether manufacturers could be held liable if an FDA-approved device injured a patient when the product was employed for an off-label, unapproved use. The Oklahoma Federal Court and the 10th Circuit Court of Appeals had both previously ruled in industry’s favor.


Related Content

Unlocking Legalities: Gorsuch’s Impact May Be Felt On Free Speech, Preemption
Cervical Spine Bone Graft Gains FDA Go-Ahead
Another Medtronic Preemption Case Appealed to High Court


Related Companies